- Somebody, somewhere sure is selling shares of Amarin (AMRN -7.1%) following a U.S. district court's ruling on generic Lovaza, but it sure is difficult to discern any negativity in the market chatter.
- Leerink's Joseph Schwartz says generic Lovaza might not compete with Vascepa on price as much as on efficacy and safety.
- There's also talk that Citi and Jefferies are out defending the shares, with Citi calling a buying opportunity.
- Additionally, there are even some notable bears that seem to think the sell-off is overdone.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Wed, 8:45AM)
at Zacks.com (Mon, 9:13AM)
at Benzinga.com (Jan 13, 2015)
at CNBC.com (Feb 28, 2014)
at MarketWatch.com (Jan 21, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs